tiprankstipranks
Advertisement
Advertisement

Biomea Fusion Reports Promising Preclinical Study Results

Story Highlights
Biomea Fusion Reports Promising Preclinical Study Results

Elevate Your Investing Strategy:

An update from Biomea Fusion ( (BMEA) ) is now available.

On June 17, 2025, Biomea Fusion reported promising preclinical results from a 28-day weight loss study involving their GLP-1 RA candidate, BMF-650, in obese cynomolgus monkeys. The study demonstrated significant, dose-dependent weight loss and reduced food intake, positioning BMF-650 favorably against other oral GLP-1 RAs in development. These findings support the company’s strategy to advance BMF-650 into clinical trials, with an Investigational New Drug submission planned for the second half of 2025, potentially impacting their market positioning and offering new options for stakeholders in diabetes and obesity treatment.

The most recent analyst rating on (BMEA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Biomea Fusion stock, see the BMEA Stock Forecast page.

Spark’s Take on BMEA Stock

According to Spark, TipRanks’ AI Analyst, BMEA is a Underperform.

Biomea Fusion’s overall stock score is significantly impacted by its poor financial performance and bearish technical indicators. The company’s inability to generate revenue and negative cash flows are major concerns, despite a low debt level. The technical analysis further highlights a negative trend, with the stock trading below key moving averages. Lastly, the lack of positive valuation metrics, such as a negative P/E ratio and absence of a dividend yield, further depresses the score.

To see Spark’s full report on BMEA stock, click here.

More about Biomea Fusion

Biomea Fusion is a company operating in the diabetes and obesity industry, focusing on developing oral small molecules. Their primary products include investigational drugs like BMF-650, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), and Icovamenib, a menin inhibitor. The company aims to address unmet needs in diabetes management by enhancing insulin production and offering potential disease-modifying therapies.

Average Trading Volume: 1,937,039

Technical Sentiment Signal: Hold

Current Market Cap: $98.82M

See more insights into BMEA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1